Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Journal of hematology & oncology - 15 Jul 2014

Wu Zhiyuan, Zhang Xinju, Xu Xiao, Chen Yuming, Hu Tingting, Kang Zhihua, Li Shibao, Wang Hua, Liu Weiwei, Ma Xiaochao, Guan Ming

Abstract excerpt

Mutations in JAK2, MPL and CALR are highly relevant to the Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs). We performed high resolution melting analysis and Sanger sequencing together with T-A cloning to elucidate the unique mutation profile of these genes, in Chinese patients with MPNs. Peripheral blood DNA samples were obtained from 80 patients with polycythemia vera (PV), 80 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calreticulin

Share to DNA Mutational Analysis

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Philadelphia Chromosome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 25023898
DOI: 10.1186/s13045-014-0048-6
PMCID: PMC4223390

Genes

CALR
JAK2
MPL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.PMID 25023898Read ↗

JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.Semantic proximity Read ↗

CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.Semantic proximity Read ↗

[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].Semantic proximity Read ↗

CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Semantic proximity Read ↗

JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasmsSemantic proximity Read ↗

JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasmsSemantic proximity Read ↗

Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL.Semantic proximity Read ↗

Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics.Semantic proximity Read ↗

Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.Semantic proximity Read ↗

A Comparison of Two Molecular Methods for Detecting CALR Mutations in Myeloproliferative Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.